Patents by Inventor Eric Hatterer

Eric Hatterer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230295348
    Abstract: The present disclosure provides compositions of bispecific antibodies useful in selective cytokine activation on immune cells. The present disclosure also provides compositions of bispecific antibodies useful for treatment of cancers that express tumor associated antigens.
    Type: Application
    Filed: January 24, 2023
    Publication date: September 21, 2023
    Inventors: Nicolas FISCHER, Julien MONTORFANI, Limin SHANG, Eric HATTERER
  • Publication number: 20230287146
    Abstract: The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human ??-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 14, 2023
    Inventors: Eric HATTERER, Anja SECKINGER, Dirk HOSE
  • Patent number: 10556960
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 11, 2020
    Assignee: NovImmune SA
    Inventors: Cristina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • Publication number: 20170298140
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: Cristina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • Patent number: 9688769
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: June 27, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Christina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer
  • Publication number: 20150110811
    Abstract: This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Inventors: Christina de Min, Limin Shang, Emmanuel Monnet, Greg Elson, Eric Hatterer